

DRUG THERAPY DAY



Wednesday, June 18, 2025

0800-1515

Four Points by Sheraton London, 1150 Wellington Rd.

Presented by the Division of Clinical Pharmacology and Toxicology

Overall Conference Learning Objectives:

By the end of this program, participants will be able to:

1. Describe therapeutic issues of relevance for drug treatments for children
2. Judge the safety of therapeutic options for the management of insomnia in pregnancy
3. Assess the benefits and limitations of medications for common neurological conditions such as stroke, epilepsy, migraine and multiple sclerosis
4. Discuss medications frequently used in patients with inflammatory bowel disease (IBD)
5. Review current pharmacology topics, such as interventions for asthma and osteoporosis therapies
6. Evaluate the potential impacts of inhaled medications on planetary health
7. Review common family medicine and pharmacist prescribing issues

AGENDA

08:00 – 08:30 Registration, Coffee/Tea and Light Breakfast

08:30 – 08:45 Welcome and Opening Remarks: Dr. Richard Kim

Session 1 – Pediatrics – Therapeutic Issues in Drug Treatment for Pregnant Women and Children

Moderator: Dr. Facundo Garcia-Bournissen, Department of Paediatrics, London Health Sciences Centre

Time	Topic/Speaker
08:45 - 09:05	Chronic pain - (non-opioid) options for children – Dr. Raju Poolacherla, Department of Anesthesia and Perioperative Medicine <u>Objectives:</u> 1. Discuss potential options for the management of chronic pain in children 2. Provide information to evaluate the risk/benefit ratio of chronic pain medications 3. Discuss adverse events related to chronic pain medications in children

09:05 – 09:25	Management of obesity in pediatrics – Dr. Marina Ybarra, Division of Endocrinology, Department of Pediatrics <u>Objectives:</u> 1. Review how to diagnose pediatric obesity and identify appropriate indications for starting pharmacological treatment. 2. Discuss the medications currently approved for treating pediatric obesity, including their mechanisms of action and safety. 3. Describe how to monitor the effectiveness and manage potential side effects of obesity medications in children to ensure safe and effective care.
09:25 – 09:45	The ABCs of Pediatric GE Reflux – Dr. Tejas Desai, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics <u>Objectives:</u> 1. Review the basic mechanisms of pediatric reflux and PPI medications 2. Navigate the initial treatment of pediatric reflux and when to refer 3. To Describe alternative and newer acid blocking treatments
09:45 – 10:05	Medications for insomnia in pregnancy – Dr. Cassie Fayowski, Division of General Internal Medicine, Department of Medicine <u>Objectives:</u> 1. Provide an overview of potential options for the management of insomnia in pregnancy 2. Review the potential risks of insomnia medications specifically during pregnancy 3. Compare medication options with alternative options for insomnia during pregnancy
10:05 – 10:25	Round Table Discussion

10:25 – 10:40 Nutrition Break

Session 2 – Neurology

Moderator: Dr. Daniel Hackam, Division of Clinical Pharmacology and Toxicology, Department of Medicine

Time	Topic/Speaker
10:40 – 11:00	Lipid-lowering for stroke prevention – Dr. Dan Hackam, Division of Clinical Pharmacology and Toxicology, Department of Medicine <u>Objectives:</u> 1. Review the associations of dyslipidemias with stroke. 2. Ascertain which lipid-lowering therapies are most effective in stroke prevention.

11:00 - 11:20	Seizures assessment and management – Dr. Jorge Burneo, Chair/Chief Division of Neurology, Department of Clinical Neurological Sciences <u>Objectives:</u> 1. Describe how to differentiate unprovoked from provoked seizures 2. Diagnose epilepsy 3. Differentiate between focal and generalized epilepsy 4. Start treatment in those with epilepsy 5. Initiate work-up for those with seizures
11:20 - 11:40	Pharmacological Advances in Multiple Sclerosis: Optimizing Treatment Strategies - Dr. Courtney Casserly, Department of Clinical Neurological Sciences <u>Objectives:</u> 1. Review the pharmacological mechanisms of recently approved MS therapies and their roles in disease modification. 2. Discuss practical considerations for initiating, switching, and monitoring MS medications in clinical practice. 3. Evaluate the management of common medication-related side effects and complications in MS care.
11:40 – 12:00	Optimizing Migraine Management: Guide to Treatment Strategies – Dr. Tommy Chan, Department of Clinical Neurological Sciences <u>Objectives:</u> 1. Outline the mechanisms of action, efficacy, and safety profiles of emerging therapies for migraine, including CGRP monoclonal antibodies and gepants. 2. Develop effective interprofessional communication strategies to optimize migraine management plans, including medication layering. 3. Empower pharmacists and physicians to recognize and address barriers to medication access and adherence in patients with migraine.
12:00 – 12:20	Round Table Discussion

12:20 noon – 1:10PM Lunch

Session 3 – Keynote Speaker

Moderator: Dr. Richard Kim, Chair, Division of Clinical Pharmacology and Toxicology, Department of Medicine

Time	Topic/Speaker
1:10 - 1:45	Evolving Management Strategies in Inflammatory Bowel Disease: New Targets and New Mechanisms - Dr. Jamie Gregor – Division of Gastroenterology, Department of Medicine <u>Objectives:</u> 1. Discuss improving prognosis with targets other than symptoms and steroid avoidance 2. Review some of the newer mechanistic approaches that may be employed therapeutically

	3. Consider patient profiles, both clinical and genetic, that may aid in the decision-making process
--	--

1:45 – 2:00 Nutrition Break

Session 4 – Therapeutic Update

Moderator: Dr. Steven Gryn, Division of Clinical Pharmacology and Toxicology, Department of Medicine

Time	Topic/Speaker
2:00 - 2:10	Can our prescribing patterns save the planet?: Planetary health and sustainable inhaler prescribing – Dr. Connie MacKenzie, Assistant Medical Director Ontario/Manitoba/Nunavut Poison Centre, Division of Clinical Pharmacology and Toxicology, Division of Respiriology, Department of Medicine <u>Objectives:</u> 1. Discuss the role of inhalers in greenhouse gas emissions. 2. Develop an approach to sustainable inhaler prescribing.
2:10 - 2:20	Precision Medicine in Asthma Care – Dr. Anurag Bhalla, Division of Respiriology, Department of Medicine <u>Objectives:</u> 1. Discuss the heterogeneity in asthma and need for advanced asthma endotyping 2. Describe novel asthma treatments 3. Develop an approach to asthma management
2:20 - 2:30	Osteoporosis Treatment in 2025 – Dr. Nadeen Al Baz, Fellow, Division of Geriatric Medicine, Department of Medicine <u>Objectives:</u> 1. Review new pharmacotherapy for osteoporosis 2. Discuss when to refer to specialty osteoporosis clinics
2:30 – 2:40	Common Prescribing Dilemmas for Family Physicians and Pharmacists – Denise Keller, Pharmacist, Personalized Medicine Program, London Health Sciences Centre <u>Objectives:</u> 1. Recognize common prescribing dilemmas 2. Develop and consider solutions to common prescribing dilemmas
2:40 – 3:00	Round table Discussions

3:00 – 3:15 p.m. **Closing remarks and completion of the program evaluation**

25% of this program is dedicated to participant interaction.

Course Credits

CFPC (Mainpro+ Certified Activity)

This activity meets the certification criteria of the College of Family Physicians of Canada and has been certified by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University for up to 5.00 Mainpro+® Certified Activity credits.

For RCPSC (MOC Section 1)

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University. You may claim a maximum of 5.00 hours (credits are automatically calculated).

Each participant should claim only those hours of credit that he/she actually spend participating in the educational program.

Non-Financial Sponsorship Statement - This program has received no financial support.

Conference Site

Four Points by Sheraton located at 1150 Wellington Rd. London, Ontario. Parking is available on site (free of charge). Please Park at the rear of the main building.

Registration

To register on-line: https://www.schulich.uwo.ca/clinpharm/about_us/news/2025/drug_therapy_day_2025.html

Early Bird Registration	\$160.00 (before June 2, 2025)
After Early Bird Registration	\$180.00 (before June 11, 2025)
Student (with proof)	\$75.00
Onsite Registration (limited to 10 attendees)	\$225.00

NOTE: Credit card payments will be processed through London Health Sciences Centre Research Institute (LHSCRI) Finance Department.